Preswitch Regimens Associated With Weight Gain Among Persons With HIV who Switch to Integrase Inhibitor–Containing Regimens
Preswitch regimens containing efavirenz and TDF were associated with significant weight gain after switching to INSTI-based regimens. Our findings support the hypothesis that the weight gain observed with switching to INSTI-based regimens could be driven by stopping medications with weight-suppressing properties.
Authors
- Nwora Lance Okeke (ORCID: https://orcid.org/0000-0003-4456-0176)
- Clemontina A. Davenport (ORCID: https://orcid.org/0000-0003-3875-7466)
- Melissa K. Cutshaw (ORCID: https://orcid.org/0000-0002-9423-8399)
- Mahmoud Harding
Institutions
- North Carolina State University (US)
- Duke University (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1093/ofid/ofae752
- Citations
- 2
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.51
Funders
- National Institutes of Health
- Center for AIDS Research, Duke University